Back to Newsroom

Sutro Aims to Deliver Anti-Tumor “Warheads” More Precisely

One of the big-tent biotechnology conferences opening this month focuses on a drug strategy that could be dubbed the targeted chemical warfare approach to cancer treatment. The much-watched developers of a new drug class called antibody-drug conjugates will convene at World ADC San Francisco 2013 on Oct. 14 to swap insights about the growing number of these armed warheads of the pharmaceutical pipeline.